Capstan Medical Secures $110M to Advance Robotic Heart Valve Treatment Technology
Capstan Medical has successfully secured $110 million in its latest round of funding to advance its innovative robotic heart valve treatment technology[1][2]. This Series C funding round, led by Eclipse and joined by participants such as Intuitive Ventures and new investor Gideon Strategic Partners, will enable Capstan to progress its mitral and tricuspid valve technologies, utilizing a robotic delivery platform for minimally invasive procedures[1][2]. The funds will support the company's efforts to conduct pivotal trials by 2026 and aim to challenge industry leaders by addressing substantial unmet patient needs in structural heart diseases[1][2].
References
Explore Further
What specific challenges does Capstan Medical face in bringing its robotic-assisted heart valve treatment technology to market by 2026?
How does Capstan Medical's robotic delivery platform differ from the existing technologies used by current industry leaders Abbott and Edwards Lifesciences?
What are the expected outcomes of Capstan Medical's first-in-human trials slated for 2025 for their mitral and tricuspid valve treatments?
In what ways might Capstan Medical's technology potentially expand into treating aortic valve conditions moving forward?
What role will the investors, such as Intuitive Ventures, play in influencing Capstan Medical’s strategic direction and development of new cardiac treatments?